Clinical systemic lupeol administration for canine oral malignant melanoma

Canine oral malignant melanoma (COMM) is the most aggressive malignant tumor in dogs. Lupeol is a triterpene extracted from various fruits and vegetables that reportedly inhibits melanoma cell proliferation in vitro and in vivo. In this study, the efficacy of subcutaneous lupeol for spontaneous COMM...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2015-01, Vol.3 (1), p.89-92
Main Authors: YOKOE, INORU, AZUMA, KAZUO, HATA, KEISHI, MUKAIYAMA, TOSHIYUKI, GOTO, TAKAHIRO, TSUKA, TAKESHI, IMAGAWA, TOMOHIRO, ITOH, NORIHIKO, MURAHATA, YUSUKE, OSAKI, TOMOHIRO, MINAMI, SABURO, OKAMOTO, YOSHIHARU
Format: Article
Language:English
Subjects:
Adjuvant chemotherapy
canine
Chemotherapy
Clinical outcomes
Clinical trials
Dogs
Drug therapy
Health aspects
lupeol
Melanoma
Metastasis
Oncology
Oral cancer
Radiation therapy
Skin cancer
Studies
Surgery
survival time
systemic injection
Terpenes
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Canine oral malignant melanoma (COMM) is the most aggressive malignant tumor in dogs. Lupeol is a triterpene extracted from various fruits and vegetables that reportedly inhibits melanoma cell proliferation in vitro and in vivo. In this study, the efficacy of subcutaneous lupeol for spontaneous COMM was evaluated. A total of 11 dogs (3, 5 and 3 dogs diagnosed with clinical stage I, II and III melanoma, respectively) were evaluated. Subcutaneous lupeol (10 mg/kg) was administered postoperatively at various time points to treat these 11 COMM cases. Of the 11 subjects, 7 exhibited no local recurrence 180 days postoperatively and no severe adverse effects were observed in any of the cases. Furthermore, no distant metastasis was observed during the experimental period. Therefore, systemic lupeol may prevent local tumor progression and distant metastasis and may be a novel adjuvant treatment for the treatment of COMM.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2014.450